Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;62(2):119-26.
doi: 10.4212/cjhp.v62i2.440.

Monitoring of serum prolactin in pediatric patients with cystic fibrosis who are receiving domperidone

Eva Cho  1 , Sharon Ho, Patricia Gerber, A George F Davidson
Affiliations

Monitoring of serum prolactin in pediatric patients with cystic fibrosis who are receiving domperidone

Eva Cho et al. Can J Hosp Pharm. 2009 Mar.

Abstract
in English, French

Background: Since 2003, it has been routine practice at Children's and Women's Health Centre of British Columbia to monitor serum levels of prolactin in pediatric patients with cystic fibrosis who are receiving domperidone. Although a pharmacologic relationship between domperidone and prolactin has been documented in the literature, there is no information about routine monitoring of prolactin, and guidance on interpretation of prolactin values is lacking.

Objectives: To characterize how prolactin levels were being used in monitoring patients with cystic fibrosis who were receiving domperidone therapy at this institution, to evaluate the need for this practice, and to formulate recommendations accordingly.

Methods: A chart review was conducted for pediatric patients with cystic fibrosis who had been receiving domperidone therapy and whose serum prolactin levels had been monitored between June 1, 2001, and October 1, 2005.

Results: A total of 219 samples had been drawn, from 49 patients, for determination of prolactin level. Of these, 100 (45.7%) were above the normal range. Of the values above the normal range, 86 (86%) led to no dosage adjustment of domperidone and 14 (14%) led to either a decrease in dose or discontinuation of therapy. None of the elevated prolactin levels were associated with supratherapeutic doses of domperidone.

Conclusion: The role of routine monitoring of prolactin in this patient population requires further study. In particular, more information is needed about prolactin levels in pediatric patients and the relationship of prolactin level to domperidone dose.

Contexte :: Depuis 2003, au Children’s and Women’s Health Centre of British Columbia, on procède systématiquement au dosage des concentrations sériques de prolactine chez les patients en pédiatrie atteints de fibrose kystique qui reçoivent de la dompéridone. Bien que la littérature fasse état d’un lien pharmacologique entre la dompéridone et la prolactine, il n’y a aucune information sur le dosage systématique de la prolactine, et on note l’absence de lignes directrices sur l’interprétation des taux de prolactine.

Objectifs :: Caractériser comment les taux de prolactine ont été utilisés pour faire le suivi des patients atteints de fibrose kystique qui recevaient de la dompéridone à cet établissement, évaluer le besoin de recourir à une telle pratique et formuler des recommandations, le cas échéant.

Méthodes :: Une analyse des dossiers médicaux des patients en pédiatrie atteints de fibrose kystique qui recevaient de la dompéridone et dont les taux sériques de prolactine ont été surveillés entre le premier juin 2001 et le premier octobre 2005 a été effectuée.

Résultats :: Au total, 219 échantillons ont été prélevés de 49 patients dans le but de déterminer les taux de prolactine. De ceux-ci, 100 (46 %) présentaient des taux au-dessus de la fourchette des valeurs normales. Pour 86 (86 %) de ces échantillons avec des valeurs au-dessus de la normale, aucun ajustement de la dose de dompéridone n’a été effectué, mais une diminution de la dose ou un arrêt du traitement a été effectué pour les 14 autres (14 %). Aucun des taux élevés de prolactine n’a été associé à des doses de dompéridone suprathérapeutiques.

Conclusion :: Le rôle du dosage systématique de la prolactine dans cette population de patient doit faire l’objet d’autres études. Plus particulièrement, il y a un besoin de plus d’information sur les taux de prolactine chez les patients en pédiatrie et sur le lien entre le taux de prolactine et la dose de dompéridone.

[Traduction par l’éditeur]

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Domperidone dosage in relation to age for 49 children with cystic fibrosis who underwent prolactin monitoring. Shaded area indicates recommended dosage at this institution at the time of the study.
Figure 2.
Figure 2.
Prolactin levels in relation to domperidone dose in the 49 study patients. Shaded area indicates recommended dosage at this institution at the time of the study.
Figure 3.
Figure 3.
Adjustments of domperidone dosage based on interpretation of prolactin values.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Barone J. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999;33(4):429–440. - PubMed
    1. Brodzicki J, Trawinska-Bartnicka M, Korzon M. Frequency, consequences and pharmacological treatment of gastroesophageal reflux in children with cystic fibrosis. Med Sci Monit. 2002;8(7):CR529–CR537. - PubMed
    1. Schappi MG, Roulet M, Rochat T, Belli DC. Electrogastrography reveals post-prandial gastric dysmotility in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2004;39(3):253–256. - PubMed
    1. Esau R, editor. 2002/2003 pediatric drug dosage guidelines. Vancouver (BC): British Columbia’s Children’s Hospital; 2002.
    1. Waseem M, Granti S, Gernsheimer J. Index of suspicion. Pediatr Rev. 2004;25:68–73. - PubMed

LinkOut - more resources